Functional assessment of HDL: Moving beyond static measures for risk assessment

Cardiovascular Drugs and Therapy

Volumn 24, Issue 1, 2010, Pages 71-75

  Rosenson, Robert S ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Cardiovascular disease; Cholesterol ester transfer protein; Cholesterol ester transfer protein inhibitors; Dalcetrapib; High density lipoprotein; Niacin; Torcetrapib

Indexed keywords

APOLIPOPROTEIN A1; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; DALCETRAPIB; EZETIMIBE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; TORCETRAPIB; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BEDTIME DOSAGE; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG FATALITY; DRUG TARGETING; DRUG WITHDRAWAL; FUNCTIONAL STATUS; HEART INFARCTION; HOT FLUSH; HUMAN; ISCHEMIC HEART DISEASE; MONOTHERAPY; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK ASSESSMENT; STROKE; UNSTABLE ANGINA PECTORIS;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; GLUCOSE; HUMANS; INSULIN; LIPASE; LIPOPROTEINS, HDL; NIACIN; QUINOLINES; RISK ASSESSMENT; RISK FACTORS; SULFHYDRYL COMPOUNDS;

EID: 77951294589     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-009-6214-3     Document Type: Article

References (15)

1. S Mora Y Cui PM Ridker 2009 Association of HDL cholesterol and apolipoprotein A-I with incident CVD across levels of LDL cholesterol in 27, 748 women Circulation 120 S507 10.1161/CIRCULATIONAHA.109.881219
2. R Frikke-Schmidt, et al. 2009 Cholesterol ester transfer protein genotype predicts anti-atherogenic lipid profile and decreased risk of ischemic heart disease, ischemic cerebrovascular disease, and death not attributable to HDL cholesterol alone Circulation 120 S1175
3. BJ Ansell M Navab S Hama N Kamranpour G Fonarow G Hough S Rahmani R Mottahedeh R Dave ST Reddy AM Fogelman 2003 Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment Circulation 108 2751 2756 10.1161/01.CIR.0000103624.14436.4B 14638544 1:CAS:528:DC%2BD3sXptV2jurw%3D (Pubitemid 37498976)
4. E Vasquez AA Sethi M Sampson AT Remaly H Chaudry 2009 O Cannon III R. "Dysfunctional" high-density lipoprotein despite normal cholesterol content in sedentary obese women Circulation 120 S470
5. AV Khera A Rodriques M de la Lioera-Moya GH Rothblatt DJ Rader 2009 Serum cholesterol efflux capacity, a measure of HDL-C quality, varies according to coronary artery disease status independently of HDL-C quantity Circulation 120 S469
6. T Hara T Ishida Y Kojima K-I Hirata 2009 Inactivation of endothelial lipase increases anti-inflammatory HDL particles Circulation 120 S469
7. C Besler K Heinrich L Rohrer K Yonekawa C Doerriers C Manes, et al. 2009 Mechanisms leading to impaired endothelial-vasoprotective properties of high density lipoprotein (HDL) in patients with coronary disease (CAD) Circulation 120 S1009
8. E Holy SF Stampfli A Akhmedov G Camici TF Luscher FC Tanner 2009 High-density lipoprotein (HDL) from healthy subjects, but not from patients with coronary artery disease, exerts anti-thrombotic effects on human endothelial cells Circulation 120 S1099 10.1161/CIRCULATIONAHA.108.787390 1:CAS:528:DC%2BD1MXhtFamsLrJ
9. BG Drew SJ Duffy JM Forbes J Chin-Dusting DM Kaye BE Kemp D Sviridov GR Steinberg BA Kingwell 2009 High density lipoprotein modulates glucose metabolism by multiple mechanisms Circulation 120 S468
10. PJ Barter M Caulfield M Eriksson SM Griudy JJP Kastelein M Komajda J Lopez-Sendon ILLUMINATE Investigatros, et al. 2007 Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2109 2122 10.1056/NEJMoa0706628 17984165 1:CAS:528:DC%2BD2sXhtlGns7bL (Pubitemid 350146106)
11. ESG Stroes JJP Kastelein A Benardeau O Kuhlmann D Blum LA Campos, et al. 2009 B J Pharmacol 158 1763 1770 10.1111/j.1476-5381.2009.00460.x 1:CAS:528:DC%2BD1MXhs1Whtr%2FL
12. C Maugeais C Magg G Dernick H Matile E von der Mark P Pflieger, et al. 2009 Dalcetrapib binds to and changes the conformation of CETP in a unique manner (differing to that observed with torcetrapib) Circulation 120 S445 10.1161/CIRCULATIONAHA.109.861633
13. EJ Niesor H Okamoto C Naugeais E von der Mark M Brousse D Blum-Kaelin E Chaput M Katutani 2009 The effects of dalcetrapib on macrophage reverse cholesterol transport in a rodent model Circulation 120 S468
14. PJ Devine MA Turco AJ Taylor 2007 Design and rationale of the ARBITER 6 trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)- 6-HDL and LDL treatment strategies in atherosclerosis (HALTS) Cardiovasc Drugs Ther 21 221 225 10.1007/s10557-007-6020-8 17404825 1:CAS:528:DC%2BD2sXlslCmtrg%3D (Pubitemid 46817479)
15. AJ Taylor TC Villnes EJ Stanek PJ Devine L Griffen M Miller, et al. 2009 Extended-release niacin or ezetimibe and carotid intima-media thickness N Engl J Med 361 2113 2122 10.1056/NEJMoa0907569 19915217 1:CAS:528:DC%2BD1MXhsFSnsLzP